Bloomberg biotech “M&A matrix” shows purported likelihood of acquiring companies to acquire:
The second graphic in the article (see link below) shows the amount of 2015-2016 M&A by each acquiring company; ABBV is the leader by a very wide margin thanks to the $21B PCYC deal (#msg-111425234).